Value of the new bone classification system in pediatric renal osteodystrophy

Clinical Journal of the American Society of Nephrology

Volumn 5, Issue 10, 2010, Pages 1860-1866

  Bakkaloglu, Sevcan A ^a,b   Wesseling Perry, Katherine ^a   Pereira, Renata C ^a   Gales, Barbara ^a   Wang, He Jing ^a   Elashoff, Robert M ^a   Salusky, Isidro B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; PARATHYROID HORMONE;

ADOLESCENT; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE MINERALIZATION; BONE TURNOVER; BONE VOLUME; CALCIUM BLOOD LEVEL; CHILD; CLINICAL ASSESSMENT; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PEDIATRICS; PRESCHOOL CHILD; RENAL OSTEODYSTROPHY; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ALGORITHMS; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BIOPSY; BONE REMODELING; CALCIFICATION, PHYSIOLOGIC; CALCIUM; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; FEMALE; HEALTH STATUS INDICATORS; HUMANS; ILIUM; INFANT; LOS ANGELES; MALE; ORGAN SIZE; PARATHYROID HORMONE; PERITONEAL DIALYSIS; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; RENAL OSTEODYSTROPHY; TERMINOLOGY AS TOPIC; YOUNG ADULT;

EID: 77958590277     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01330210     Document Type: Article

References (28)

1. Sherrard DJ, Hercz G, Pei Y, Maloney NA, Greenwood C, Manuel A, Saiphoo C, Fenton SS, Segre GV: The spectrum of bone disease in end-stage renal failure - an evolving disorder. Kidney Int 43: 436-442, 1993
2. Salusky IB, Brill J, Oppenheim W, Goodman WG: Features of renal osteodystrophy in pediatric patients receiving regular peritoneal dialysis. Semin Nephrol 9: 37-42, 1989
3. Salusky IB, Ramirez JA, Oppenheim W, Gales B, Segre GV, Goodman WG: Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Kidney Int 45: 253-258, 1994
4. Groothoff JW, Offringa M, Van Eck-Smit BL, Gruppen MP, Van De Kar NJ, Wolff ED, Lilien MR, Davin JC, Heymans HS, Dekker FW: Severe bone disease and low bone mineral density after juvenile renal failure. Kidney Int 63: 266-275, 2003
5. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G: Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69: 1945-1953, 2006
6. K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis 46: S1-S121. 2005
7. Salusky IB, Kuizon BD, Belin TR, Ramirez JA, Gales B, Segre GV, Goodman WG: Intermittent calcitriol therapy in secondary hyperparathyroidism: A comparison between oral and intraperitoneal administration. Kidney Int 54: 907-914, 1998
8. Kuizon BD, Goodman WG, Juppner H, Boechat I, Nelson P, Gales B, Salusky IB: Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD. Kidney Int 53: 205-211, 1998 (Pubitemid 28066923)
9. Salusky IB, Goodman WG, Kuizon BD, Lavigne JR, Zahranik RJ, Gales B, Wang HJ, Elashoff RM, Juppner H: Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int 63: 1801-1808, 2003
10. Salusky IB, Goodman WG, Sahney S, Gales B, Perilloux A, Wang HJ, Elashoff RM, Juppner H: Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols. J Am Soc Nephrol 16: 2501-2508, 2005 (Pubitemid 41725070)
11. 3 and active vitamin D sterols. Pediatr Nephrol 24: 1355-1361, 2009
12. Wesseling-Perry K, Pereira RC, Wang H, Elashoff RM, Sahney S, Gales B, Juppner H, Salusky IB: Relationship between plasma FGF-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab 94: 511-517, 2009
13. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR: Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2: 595-610, 1987
14. Sanchez CP, Salusky IB, Kuizon BD, Ramirez JA, Gales B, Ettenger RB, Goodman WG: Bone disease in children and adolescents undergoing successful renal transplantation. Kidney Int 53: 1358-1364, 1998
15. Nussbaum SR, Zahradnik RJ, Lavigne JR, Brennan GL, Nozawa-Ung K, Kim LY, Keutmann HT, Wang CA, Potts JT Jr, Segre GV: Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 33: 1364-1367, 1987
16. Autosomal dominant hypophosphataemic rickets is asso- ciated with mutations in FGF23. ADHR Consortium. Nat Genet 26: 345-348, 2000
17. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium Nat Genet 11: 130-136, 1995
18. DeVille J, Thorp ML, Tobin L, Gray E, Johnson ES, Smith DH: Effect of ergocalciferol supplementation on serum parathyroid hormone and serum 25-hydroxyvitamin D in chronic kidney disease. Nephrology (Carlton) 11: 555-559, 2006
19. Zisman AL, Hristova M, Ho LT, Sprague SM: Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol 27: 36-43, 2007
20. Langman CB, Mazur AT, Baron R, Norman ME: 25-hydroxyvitamin D3 (calcifediol) therapy of juvenile renal osteodystrophy: Beneficial effect on linear growth velocity. J Pediatr 100: 815-820, 1982
21. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB: Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64: 2272-2279, 2003
22. Salusky IB, Coburn JW, Brill J, Foley J, Slatopolsky E, Fine RN, Goodman WG: Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD. Kidney Int 33: 975-982, 1988
23. Kuizon BD, Salusky IB: Intermittent calcitriol therapy and growth in children with chronic renal failure. Miner Electrolyte Metab 24: 290-295, 1998
24. Monier-Faugere MC, Geng Z, Mawad H, Friedler RM, Gao P, Cantor TL, Malluche HH: Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. Kidney Int 60: 1460-1468, 2001
25. Malluche HH, Siami GA, Swanepoel C, Wang GH, Mawad H, Confer S, Smith M, Pratt RD, Monier-Faugere MC: Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years. Clin Nephrol 70: 284-295, 2008
26. Adragao T, Herberth J, Monier-Faugere MC, Branscum AJ, Ferreira A, Frazao JM, Dias CJ, Malluche HH: Low bone volume - a risk factor for coronary calcifications in hemodialysis patients. Clin J Am Soc Nephrol 4: 450-455, 2009
27. Chertow GM, Burke SK, Raggi P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62: 245-252, 2002
28. Martin KJ, Juppner H, Sherrard DJ, Goodman WG, Kaplan MR, Nassar G, Campbell P, Curzi M, Charytan C, McCary LC, Guo MD, Turner SA, Bushinsky DA: First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl. Kidney Int 68: 1236-1243, 2005